Skip to main content
Fig. 3 | BMC Cardiovascular Disorders

Fig. 3

From: Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Fig. 3

Mean CHA2DS2-VASc and HAS-BLED [calculated] score distribution by dose groups. a CHA2DS2-VASc score distribution(7): Low risk: Score = 0 for men, 1 for women. Intermediate risk: Score = 1 for men, 2 for women. High risk: Score ≥ 2 for men, > 2 for women. b HAS-BLED score distribution: Low risk: Score < 2. Intermediate risk: Score 2–3. High risk: Score ≥ 4

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us